trending Market Intelligence /marketintelligence/en/news-insights/trending/e1k0cqh5pq0cu1yzyxckzq2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Catalent completes tender offer for Juniper Pharmaceuticals acquisition

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Catalent completes tender offer for Juniper Pharmaceuticals acquisition

Catalent Inc. completed the tender offer to acquire all outstanding shares of Juniper Pharmaceuticals Inc. for $11.50 apiece.

A total of 9,285,239 common shares, representing about 82% of Juniper's outstanding common shares, were validly tendered and not withdrawn at midnight ET on Aug. 13, the offer's expiration date.

Catalent said it expects to close the merger Aug. 14. All remaining shares will be converted into a right to receive $11.50 in cash per share upon the deal's closing.

Following merger completion, Juniper will be a wholly owned unit of Catalent and its common shares will be delisted from the Nasdaq Global Select Market.